Login
$IMNM
$17.69 +$0.08 (0.45%) After hours

$IMNM 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)

05 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

THIS STOCK ISSUANCE AGREEMENT (“Agreement”) is entered into as of October 2, 2026, by and between Bristol-Myers Squibb Company, a Delaware corporation having offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”...

11 Aug 2026 8-K: Results of Operations and Financial Condition

Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Immunome, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on June 9, 2026 (the “Annual Meeting”). As of April 16, 2026, the record date for the Annual Meeting, 113,249,519 shares of common stock were outstanding and ent...

12 May 2026 8-K: Results of Operations and Financial Condition

New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors

03 Mar 2026 8-K: Results of Operations and Financial Condition

New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026

17 Dec 2025 8-K: Other Events

18,625,000 Shares of Common Stock, par value $0.0001 per share

15 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Corporate Presentation Transformative Targeted Therapeutics December 2025 Exhibit 99.2

06 Nov 2025 8-K: Results of Operations and Financial Condition

BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September 30, 2025, and pro...

06 Aug 2025 8-K: Results of Operations and Financial Condition

BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided ...

11 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Immunome, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders on June 10, 2025 (the “Annual Meeting”). As of April 21, 2025, the record date for the Annual Meeting, 87,011,822 shares of common stock were outstanding and ent...

12 May 2025 8-K: Results of Operations and Financial Condition; Other Events

BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided...

19 Mar 2025 8-K: Results of Operations and Financial Condition

Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025.

30 Jan 2025 8-K: Other Events

19,354,839 Shares of Common Stock, par value $0.0001 per share

29 Jan 2025 8-K: Results of Operations and Financial Condition; Other Events

On January 29, 2025, the Company announced the commencement of an underwritten public offering of its common stock (the Offering). The Company will file with the Securities and Exchange Commission (SEC) a preliminary prospectus supplemen...

23 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Congratulations! In recognition of your continued hard work, dedication and loyalty to the success of Immunome, Inc. (the “Company”), the Company is pleased to offer you the relocation package described below. Capitalized terms used but ...

13 Nov 2024 8-K: Results of Operations and Financial Condition

BOTHELL, Wash. –Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the third quarter ended September 30...

29 Oct 2024 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

08 Oct 2024 8-K: Other Events

(a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, a...

12 Aug 2024 8-K: Results of Operations and Financial Condition

BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the second quarter ended June 30, 2...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support